CV301
AXP000180.1 · Cancer vaccine
- Platform
- MVA-BN prime, fowlpox boost
- Targets
- CEACAM5; MUC1
- Originator
- Bavarian Nordic
- Sponsor
- Bavarian Nordic
Names
| Name | Type | Source |
|---|---|---|
| CV301 | preferred name, code | curator, ncit |
| CV301-V/F | code | ncit |
| CVAC-301 | code | ncit |
| FPV-CV301 | code | ncit |
| MVA-BN-CV301 | code | ncit |
| PANVAC ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA-BN prime; fowlpox (FPV-CV301) boost
- Replication
- non replicating
- Modifications
- CEA, MUC-1 and TRICOM cassettes in MVA-BN; fowlpox boost with the same cassette
- Transgenes
- CEACAM5, MUC1, CD80, ICAM1, CD58
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C131129
Approvals
No regulatory approval recorded.
Clinical trials (7)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04574583 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | Completed | Phase 1/2 | 2020-11-24 | 2023-02-07 | 12 | Metastatic Cancer; Solid Tumors |
| NCT04491955 | Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers | Completed | Phase 2 | 2020-09-22 | 2022-10-25 | 32 | Colorectal Cancers; Small Bowel Cancers |
| NCT03628716 | CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed | Phase 2 | 2018-09-18 | 2020-11-03 | 43 | Bladder Cancer |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | Terminated | Phase 1/2 | 2018-08-08 | 2021-08-30 | 8 | Colorectal Adenocarcinoma; Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Pancreatic Adenocarcinoma |
| NCT03547999 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | Terminated | Phase 2 | 2018-06-26 | 2024-03-13 | 17 | Metastatic Colorectal Cancer |
| NCT03315871 | Combination Immunotherapy in Biochemically Recurrent Prostate Cancer | Completed | Phase 2 | 2018-03-20 | 2024-06-04 | 40 | Prostate Cancer |
| NCT02840994 | A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer | Completed | Phase 1 | 2016-12 | 2020-01 | 24 | Non-small Cell Lung Cancer (NSCLC) |
Unconfirmed matches (5)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT02015104 | Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG | Completed | Phase 2 | 2013-12-18 | 2018-09-18 | 32 | Bladder Cancer | intervention named: PANVAC |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | Active not recruiting | Phase 1 | 2010-02-01 | 2021-09-02 | 18 | Locally Advanced Pancreatic Adenocarcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7 | name in intervention: PANVAC |
| NCT00179309 | Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer | Completed | Phase 2 | 2005-09 | 2013-02 | 48 | Breast Cancer | name in intervention: PANVAC |
| NCT00088413 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | Completed | Phase 1/2 | 2004-07-21 | 2018-04-01 | 51 | Adenocarcinoma; Breast Cancer; Colorectal Cancer; Ovarian Cancer | name in intervention: PANVAC |
| NCT00088660 | PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen | Unknown | Phase 3 | 2004-06 | 250 | Pancreatic Cancer | name in intervention: PANVAC |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41520164 | The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer. | The oncologist | 2026 | cited by trial NCT04491955 |
| PMID 35998004 | Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma. | Cancer immunology, immunotherapy : CII | 2023 | name in title: CV301 |
| PMID 36054490 | Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer. | International journal of cancer | 2023 | cited by trial NCT02840994 |
Unconfirmed matches (2)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40781051 | Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer. | Urologic oncology | 2025 | name in title: PANVAC |
| PMID 26291768 | Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. | JAMA oncology | 2015 | name in title: PANVAC |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 31110074 | A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | name in title: CV301 |
| PMID 31227502 | When Cancer Vaccines Go Viral. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | name in abstract: CV301 |
Unconfirmed matches (6)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 22380820 | Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm. | Expert review of vaccines | 2012 | name in title: PANVAC |
| PMID 22892452 | Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2012 | name in title: PANVAC |
| PMID 17373905 | PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. | Expert opinion on biological therapy | 2007 | name in title: PANVAC |
| PMID 16451103 | Development of the PANVAC-VF vaccine for pancreatic cancer. | Expert review of vaccines | 2006 | name in title: PANVAC |
| PMID 16512998 | A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. | Clinical colorectal cancer | 2006 | name in title: PANVAC |
| PMID 16800982 | A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). | Clinical breast cancer | 2006 | name in title: PANVAC |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC010598 | Human Immune Responses to Tumor Antigens for Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2012–2025 | name in abstract: MVA-BN-CV301 |
| ZIABC011906 | CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer | DIVISION OF BASIC SCIENCES - NCI | RAJAN, ARUN | 2019–2025 | name in title: CV301 |
| ZIDDC000075 | NIDCD Core for Clinical Research and Care | NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS | LEVY, JOSHUA | 2021–2025 | name in abstract: CV301 |
| ZIABC010425 | Strategies for Cancer Immunotherapy Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2009–2023 | name in abstract: MVA-BN-CV301 |
| ZIABC011547 | Cancer Immunotherapy Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | STRAUSS, JULIUS | 2014–2022 | name in abstract: MVA-BN-CV301 |
| ZIABC011865 | Breast and Other Carcinoma Clinical Trials Using Immunotherapies | DIVISION OF BASIC SCIENCES - NCI | GATTI-MAYS, MARGARET | 2019–2020 | name in abstract: MVA-BN-CV301 |
Notes
MVA-BN-CV301 prime (NCIt C143059) with FPV-CV301 boosts (NCIt C141298), encoding CEA, MUC-1 and TRICOM: the PANVAC antigen cassette rebuilt on the non-replicating MVA-BN backbone, hence a separate program from PANVAC (AXP000142). Phase 1/2 in NSCLC and bladder cancer with checkpoint inhibitors (Bavarian Nordic-sponsored). Originator/sponsor taken from the MVA-BN naming in NCIt and Bavarian Nordic press coverage; not independently confirmed here.
How to cite
CV301 (AXP000180.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000180.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.